1. HBW Insight
  2. >>Geography
  3. >>Asia

Pfizer Reorganizes Internally, Closer To Decision On Splitting Business

 
• By Wendy Diller and Malcolm Spicer

Consumer health products are grouped with vaccines and oncology drugs in Pfizer’s internal reorganization that takes effect in January 2014. Pfizer’s realignment into three organizations represents a step in the firm’s multi-year deliberation over whether to split its business.

Pfizer Inc. is reorganizing its commercial operations into three business segments led by top executives, grouping consumer health products with vaccines and oncology products, a move broadly in line with plans the firm outlined in discussions over the past two years with analysts.

Beginning Jan. 1, 2014, Pfizer will operate with an Innovative Products Group, responsible for drugs in therapeutic areas that are...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Asia

More from Geography

AESGP Annual Meeting: European OTC Market Outlook ‘Very Positive’ Thanks To Prevention Trend

 
• By David Ridley

The European OTC market grew at double the rate of the global market in the last twelve months, according to IQVIA Consumer Health, driven by a long-term trend for prevention. Consultancy Simon Kucher identifies a desire to live a longer, healthier life as the primary concern behind this trend.

AESGP Annual Meeting: Harmonizing EU VMS Max Levels Could Cost Sector Over €200m

 
• By David Ridley

Limited capacity and a two-to-three year timescale for reformulation could mean that many VMS supplements disappear from the market, warns EPPA partner Alexandra Bocquillion, speaking at the AESGP Annual Meeting in Warsaw, Poland.

EU Pharma Reform: Council Proposes Rx Exemption For Topical Antimicrobials

 
• By David Ridley

The EU Council has introduced a key amendment to Article 51 (para 1, point e) of the new pharma directive: “A medicinal product shall be subject to medical prescription where it is an antimicrobial, unless intended for topical use.”